Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [1] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Denys, Hannelore
    Martinez-Mena, Corina L.
    Martens, Marc T.
    D'Hondt, Randal G.
    Graas, Marie-Pascale L.
    Evron, Ella
    Fried, Georgeta
    Ben-Baruch, Noa E.
    Vulsteke, Christof
    Van Steenberghe, Mona M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 97 - 105
  • [2] An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
    Cicin, Irfan
    Oukkal, Mohammed
    Mahfouf, Hassen
    Mezlini, Amel
    Larbaoui, Blaha
    Ben Ahmed, Slim
    Errihani, Hassan
    Alsaleh, Khalid
    Belbaraka, Rhizlane
    Yumuk, Perran Fulden
    Goktas, Burce
    Ozguroglu, Mustafa
    EUROPEAN JOURNAL OF BREAST HEALTH, 2022, 18 (01) : 63 - 73
  • [3] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    LANCET, 2012, 379 (9816) : 633 - 640
  • [4] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
    Dent, S.
    Ammendolea, C.
    Christofides, A.
    Edwards, S.
    Incekol, D.
    Pourmirza, B.
    Kfoury, S.
    Poirier, B.
    CURRENT ONCOLOGY, 2019, 26 (01) : E70 - E80
  • [5] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Sherko Kuemmel
    Carlo A. Tondini
    Jacinta Abraham
    Zbigniew Nowecki
    Bartosz Itrych
    Erika Hitre
    Bogusława Karaszewska
    Alejandro Juárez-Ramiro
    Flavia Morales-Vásquez
    Jose Manuel Pérez-García
    Servando Cardona-Huerta
    Estefania Monturus
    Marco Sequi
    Eleonora Restuccia
    Mark Benyunes
    Miguel Martín
    Breast Cancer Research and Treatment, 2021, 187 : 467 - 476
  • [6] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Kuemmel, Sherko
    Tondini, Carlo A.
    Abraham, Jacinta
    Nowecki, Zbigniew
    Itrych, Bartosz
    Hitre, Erika
    Karaszewska, Boguslawa
    Juarez-Ramiro, Alejandro
    Morales-Vasquez, Flavia
    Perez-Garcia, Jose Manuel
    Cardona-Huerta, Servando
    Monturus, Estefania
    Sequi, Marco
    Restuccia, Eleonora
    Benyunes, Mark
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 467 - 476
  • [7] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Heo, Young-A
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 749 - 758
  • [8] Subcutaneous trastuzumab - recent evidence on efficacy and safety in HER2-positive breast cancer patients
    Pogoda, Katarzyna
    Niwinska, Anna
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (02): : 93 - 99
  • [9] Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
    Zambetti, Milvia
    Montemurro, Filippo
    Morandi, Paolo
    Zamagni, Claudio
    Brandes, Alba A.
    Bisagni, Giancarlo
    Cagossi, Katia
    Bengala, Carmelo
    Gori, Stefania
    Iannacone, Claudio
    Stell, Alessia
    Gianni, Luca
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 61 - 70
  • [10] Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)
    Yamamoto, Yutaka
    Iwata, Hiroji
    Taira, Naruto
    Masuda, Norikazu
    Takahashi, Masato
    Yoshinami, Tetsuhiro
    Ueno, Takayuki
    Toyama, Tatsuya
    Yamanaka, Takashi
    Takano, Toshimi
    Kashiwaba, Masahiro
    Tsugawa, Koichiro
    Hasegawa, Yoshie
    Tamura, Kenji
    Tada, Hiroshi
    Hara, Fumikata
    Fujisawa, Tomomi
    Niikura, Naoki
    Saji, Shigehira
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    CANCER SCIENCE, 2022, 113 (09) : 3169 - 3179
12345